Filed Pursuant to Rule 424(b)(3)
                                                      Registration No. 333-52736


PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED FEBRUARY 6, 2001


                                   PROSPECTUS


                         AVANT IMMUNOTHERAPEUTICS, INC.


                        2,127,113 Shares of Common Stock


        UNLESS THE CONTEXT OTHERWISE REQUIRES, ALL REFERENCES TO "WE," "US" OR
"OUR COMPANY" IN THIS PROSPECTUS SUPPLEMENT REFER TO AVANT IMMUNOTHERAPEUTICS,
INC. (F/K/A T-CELL SCIENCES, INC.), A DELAWARE CORPORATION.

        This prospectus supplement updates the prospectus dated February 6,
2001 relating to the offer for sale of up to an aggregate of 2,127,113 shares
of common stock, par value $.001 per share of AVANT Immunotherapeutics, Inc.
(f/k/a T Cell Sciences, Inc.) to be sold by the selling stockholders
identified in the prospectus, and any of their pledgees, donees, transferees
or other successors in interest.

        We are providing this prospectus supplement to update the table in
the prospectus under the caption "Selling Stockholders" to reflect the
transfer of shares by various selling stockholders. Lines one, two, twenty,
forty-two and sixty-nine of the table are replaced with the following
information which is based upon information provided to us by the selling
stockholders and is accurate to the best of our knowledge. Unless we indicate
otherwise, the information in this prospectus supplement is as of May 15,
2001.

SHARES OF COMMON STOCK BENEFICIALLY SHARES OF COMMON STOCK OWNED OWNED AS OF SHARES OF COMMON AFTER THE OFFERING(2) SELLING STOCKHOLDER MAY 15, 2001 STOCK OFFERED HEREBY NUMBER(1) PERCENT(2) A/W Company 25,650 25,650 0 0 Alafi Capital Company 520,384 520,384 0 0 Brian Clevinger 19,869 19,869 0 0 Mary Anne Rudloff 10,737 10,737 0 0 John Steuart 29,328 29,328 0 0 Brentmoor Investment LLC 14,519 14,519 0 0
- ------------------ (1) Assumes that all shares of common stock hereby offered by the selling stockholders are sold. (2) Based on 57,359,979 shares of common stock outstanding as of May 15, 2001. This prospectus supplement is not complete without the prospectus dated February 6, 2001, and we have not authorized anyone to deliver or use this prospectus supplement without the prospectus. THE DATE OF THIS PROSPECTUS SUPPLEMENT IS JUNE 25, 2001.